35,500 Shares in Exagen Inc. (NASDAQ:XGN) Acquired by Creative Planning

Creative Planning acquired a new stake in shares of Exagen Inc. (NASDAQ:XGN) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 35,500 shares of the company’s stock, valued at approximately $110,000.

Separately, Renaissance Technologies LLC lifted its stake in shares of Exagen by 93.3% in the second quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock worth $172,000 after buying an additional 45,476 shares in the last quarter. Institutional investors and hedge funds own 75.25% of the company’s stock.

Exagen Price Performance

Shares of XGN opened at $2.79 on Wednesday. Exagen Inc. has a twelve month low of $1.30 and a twelve month high of $3.71. The company has a market capitalization of $48.51 million, a P/E ratio of -2.88 and a beta of 1.35. The firm has a 50 day moving average of $2.84 and a 200 day moving average of $2.36. The company has a quick ratio of 4.32, a current ratio of 4.32 and a debt-to-equity ratio of 1.13.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).